103 IL-6 inhibitors in hospitalised COVID-19 patients 5 Survival analyses The Kaplan-Meier survival curves per dosing group can be found in the supplementary file. After adjustment for confounders, the 8 mg/kg group showed a better survival than fixed dose tocilizumab and sarilumab groups, but not than the low dose tocilizumab (Table 2 and Supplementary Figure 2). In a second Cox proportional hazards analysis including imputed outcome and survival time values for patients with missing data, the 8 mg/kg group has improved survival when compared with the other 3 groups (Table 3). The first extreme cases sensitivity analysis, in which all patients with an unknown outcome were assumed to have survived until the end of follow-up at day 60, showed no differences in survival between the different treatment groups between the 8 mg/kg group and the fixed dose and low dose group, but survival was slightly improved for the 8 mg/kg group compared to the sarilumab group (Supplementary Table 1). In the extreme case analysis in which all patients with an unknown outcome were assumed to have died on the day of discharge, survival was worse for all three groups than for the 8 mg/kg group (Supplementary Table 2). When only patients who were admitted to ICU during their hospital admission were included in the analysis, a difference in the unadjusted analysis was found between the different treatment groups: the 8 mg/kg and fixed dose groups had a better survival than the low dose and sarilumab groups (Supplementary Figure 3). After correction for confounding, the 8 mg/kg group showed better survival at day 60 than the sarilumab group, but no difference was found with the other two groups (Supplementary Table 3). With imputed data for missing outcome and survival time variables, similar results were found (Supplementary Table 4). Group Hazard ratio (95% CI) 8 mg/kg 1 Fixed dose tocilizumab 1.20 (1.04 to 1.39) Low dose tocilizumab 1.12 (0.97 to 1.31) Sarilumab 400mg 1.24 (1.08 to 1.42) Table 2: Multivariable Cox proportional hazards regression analysis with 60-day mortality as endpoint, correcting for age, sex, immunocompromised status and CCI, including all patients with a known outcome
RkJQdWJsaXNoZXIy MTk4NDMw